Journal of the American Society of Nephrology

August 8, 2019

New window on fibrosis

A previously unrecognized role for a cell surface receptor may open new therapeutic options for the treatment of fibrotic diseases.

By Bill Snyder
July 25, 2019

Sex differences in kidney injury

Men are more susceptible to progressive kidney disease than women; new VUMC studies point to differences in the expression and activation of the EGF receptor.

By Kelsey Herbers
December 6, 2018

Team spots clue to rare lung and kidney diseases

Pulmonary-renal syndrome (PRS) refers to a group of rare but potentially fatal conditions that nearly always are caused by a misguided attack by the body’s immune system on the lungs and kidneys. Coughing up blood and blood in the urine are telltale signs.

By Bill Snyder
August 16, 2018

YAP after acute kidney injury

Activation of the signaling protein YAP may be a target for treating acute kidney injury, which affects up to 20 percent of hospitalized patients.

By Sanjay Mishra
August 7, 2014

Study tracks new end-stage renal disease therapy

Researchers in Vanderbilt’s Division of Nephrology conducted a Phase 3 clinical trial to test the safety and efficacy of a new drug to treat patients with end-stage renal disease.

By Kathy Whitney